Senior Director, Global HEOR Marketed Product Scientist
argenx
Summary
The Senior Director, HEOR Marketed Products Scientist is accountable for the HEOR value-evidence strategy across related conditions in a branch of medicine in the argenx marketed product portfolio, specifically rheumatology with a growing portfolio expected. This person will work with Pipeline HEOR to help inform readiness of the next wave of rheumatology indications and launches.
Job description
Roles and Responsibilities
- Own the multi-year HEOR evidence generation strategy for the argenx marketed portfolio, aligned with brand, medical, market access, and pricing strategies.
- Set and defend the marketed-products HEOR investment case and budget with senior leadership; prioritize across indications, geographies, and methods.
- Serve as the HEOR representative in global brand, launch readiness, value, and evidence governance forums.
- Lead, coach, and develop HEOR scientists and matrix contributors; set scientific standards and build capability.
- Partner with Pipeline HEOR to ensure seamless hand-over of evidence responsibility for indications transitioning through Phase 3 to launch.
- Partner with Real World Evidence colleagues to align registry, claims, chart-review, and prospective observational programs with HEOR and HTA evidence needs.
- Direct scientifically rigorous HEOR research including cost-effectiveness and budget-impact models, indirect treatment comparisons, systematic reviews, burden-of-illness and cost-of-illness studies, humanistic and productivity outcomes, and preference research.
- Oversee the HEOR publication and dissemination strategy for marketed products with Scientific Communications.
- Ensure HEOR evidence and economic models are fit for purpose across global and regional HTA and payer submissions.
- Select and govern external research collaborators, academic centres, and vendors.
- Act as an argenx ambassador with external stakeholders including payers, HTA bodies, key opinion leaders, professional societies, and patient organizations.
- Develop and deliver HEOR presentations to formulary committees, HTA bodies, and other decision makers.
- Build and sustain relationships with leading HEOR thought leaders and academics.
- Translate complex value evidence into clear, compelling narratives for diverse audiences.
- Contribute to functional strategy, ways of working, standards, and vendor and platform decisions for Global HEOR.
Skills and Competencies
- Strategic leadership
- Working effectively with others
- Creativity and innovation
- Priority setting
- Technical mastery of HEOR methodology and global HTA, payer, and pricing environments
- Initiative and follow-through
- People development
- Thinking and problem solving
- Communication
Requirements
- PhD, MD, PharmD, or relevant Master's degree in health economics, outcomes research, epidemiology, public health, pharmacy, or a related discipline
- 10+ years in the pharmaceutical or biotech industry
- Strong knowledge of drug development, commercialization, and regulatory and compliance requirements
- 8+ years of HEOR experience
- Demonstrated depth in health economic modelling, evidence synthesis, epidemiology, quality-of-life and patient-reported outcomes, real-world evidence, and communication of HEOR results to decision makers
- Demonstrated experience leading HEOR strategy for marketed products, including multi-indication portfolios, and accountability for multi-million budgets
- Launch experience with orphan or specialty medicines
- Strong understanding of US payer and market access dynamics and of HTA requirements in ex-US markets
- Ability to lead cross-functional teams and influence senior stakeholders without formal authority
- Strong publication record and recognized external presence in the HEOR community
- Excellent written and verbal communication and interpersonal skills; fluent English
- Ability to travel up to 20% of time as needed
- Experience in rare disease, immunology, or rheumatology is strongly preferred
Benefits
- Retirement Savings Plans
- Health Benefits
- Short-term Incentive Program
- Long-term Incentive Program
Company overview
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Founded in 2008 and headquartered in Amsterdam, Netherlands with major operations in Boston, Massachusetts, argenx is a commercial-stage, fully-integrated biopharma company developing a deep pipeline of differentiated antibody-based therapies. The company's core innovation engine is its Immunology Innovation Program (IIP), which partners with leading academic researchers to translate immunology breakthroughs into novel medicines. argenx has developed and commercialized VYVGART, the first approved FcRn blocker available in more than 30 countries for conditions like generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP). The company leverages its proprietary SIMPLE ANTIBODY™ platform technology based on llama immune systems to access novel disease biology targets, combined with antibody engineering technologies like NHANCE™ and ABDEG™ to enhance therapeutic properties. With over 1,500 employees globally and listed on both Euronext Brussels and Nasdaq, argenx maintains a robust pipeline including empasiprubart (C2 inhibitor) in Phase 3 trials and several earlier-stage experimental medicines targeting various autoimmune conditions.